Kopran Quarterly Results
Kopran quarterly results. In Mar 2026, Kopran (KOPRAN) reported revenue ₹234 Cr and net profit ₹19 Cr — revenue +33.0% YoY. Check KOPRAN company valuation to track the company's total market size over time.
KOPRAN Quarterly Results — Revenue, Profit & EPS Highlights
Kopran latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit KOPRAN screener.
- Revenue of ₹234 Cr in Mar 2026 (+50.0% vs Jun 2026, +33.0% vs Mar 2025)
- Net Profit of ₹19 Cr in Mar 2026 (+171.4% vs Jun 2026, +90.0% vs Mar 2025)
- EBITDA of ₹33 Cr in Mar 2026 (+83.3% vs Jun 2026)
- Operating Margin of 14.0% in Mar 2026 (+4.0pp vs Jun 2026)
- Earnings Per Share of ₹3.91 in Mar 2026 (+181.3% vs Jun 2026)
Kopran Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KOPRAN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 234 | 156 | 118 | 176 | 138 | 50.0% | 33.0% |
| Net Profit (₹ Cr) | 19 | 7 | -10 | 10 | 7 | - | - |
| EBITDA (₹ Cr) | 33 | 18 | -5 | 20 | 17 | - | - |
| EPS (₹) | 3.91 | 1.39 | -2.06 | 2.00 | 1.54 | - | - |
| Operating Margin (%) | 14.0% | 10.0% | -4.0% | 10.0% | 10.0% | - | - |
KOPRAN Share Price Trend — 1-Year Movement Across Quarterly Results
Kopran 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review KOPRAN price earnings ratio to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KOPRAN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kopran latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores